Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study.
Infect Dis Clin Pract (Baltim Md)
; 29(5): e282-e286, 2021 Sep.
Article
en En
| MEDLINE
| ID: mdl-34539162
ABSTRACT
BACKGROUND:
Remdesivir treatment, like most antiviral drugs, is likely to be most effective when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of remdesivir for the treatment of COVID-19 remains unclear.OBJECTIVES:
The aim of this study was to determine whether early treatment with remdesivir improves clinicaloutcomes:
length of stay, need for mechanical ventilation, and death.METHODS:
We conducted a retrospective observational study of patients hospitalized with COVID-19 who received remdesivir therapy within 10 days of symptom onset at a large health system in Georgia, United States.RESULTS:
We identified a total of 475 patients. Initiation of therapy 3 days or less from first positive SARS-CoV-2 improved length of stay (15.7 days) compared with those started on therapy more than 3 days after a positive test (19.3 days) (P = 0.03). In the ≤3 day group, further reduction in length of stay was seen in those with lower oxygen requirement at baseline (P < 0.0001). Length of stay was lower in the ≤3 day group both with and without the use of corticosteroids (P = 0.0003). The odds of requiring mechanical ventilation were higher for the >3 day group compared with the ≤3 day group (odds ratio, 1.5; 95% confidence interval, 0.8-2.7), and the odds of death were higher for the >3 day group versus the ≤3 day group (odds ratio, 1.74; 95% confidence interval, 0.9-3.2).CONCLUSIONS:
Our data show that early treatment with remdesivir in patients hospitalized with COVID-19 shortened length of stay.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
4_TD
Problema de salud:
4_covid_19
Tipo de estudio:
Observational_studies
Idioma:
En
Revista:
Infect Dis Clin Pract (Baltim Md)
Año:
2021
Tipo del documento:
Article